Drug intelligence / Profile preview

metoprolol + amlodipine

Development stage
Unknown
Lead developer
AstraZeneca
Modality
Small Molecules
Administration
Oral
01

Overview

Metoprolol + amlodipine is a fixed-dose combination of two antihypertensive agents used primarily for the treatment of hypertension (high blood pressure) and angina pectoris (chest pain). Metoprolol is a beta-blocker that selectively blocks beta1 adrenergic receptor in the heart, reducing heart rate and cardiac output. Amlodipine is a calcium channel blocker that inhibits calcium ion influx into vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced peripheral vascular resistance. Together, these drugs lower blood pressure more effectively than either agent alone, improve treatment adherence by combining two medications into one pill, and reduce the risk of cardiovascular events such as stroke or heart attack[1][3][4][5]. The combination has been shown to be safe, well-tolerated, and effective in clinical studies[3][8].

Brand names
Prolomet AMAmtas-MMetpure-AMAmlovas-MAmlopin-MVinicor-AMStarpress-AMEmbeta AMAmlong MT
Other names
amlodipine + metoprolol succinate
02

Targets

ADRB1 (β1)CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)

Beyond the preview

Go deeper on metoprolol + amlodipine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on metoprolol + amlodipine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call